Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Advanced Medical Equipment & Technology

Delayed Nasdaq Other stock markets 03:47:12 2024-05-20 pm EDT			5-day change	1st Jan Change
8.71 ^USD	+11.52%		+21.40%	-29.08%

May. 14	Pulse Biosciences Appoints Burke Barrett as President, CEO	MT
May. 14	Pulse Biosciences, Inc Announces CEO Changes	CI

Pulse Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 10, 2022 at 04:29 pm EST

Pulse Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 18.04 million compared to USD 14.28 million a year ago. Basic loss per share from continuing operations was USD 0.49 compared to USD 0.48 a year ago.
For the nine months, revenue was USD 0.709 million compared to USD 0.574 million a year ago. Net loss was USD 49.31 million compared to USD 48.24 million a year ago. Basic loss per share from continuing operations was USD 1.5 compared to USD 1.76 a year ago.

Latest news about Pulse Biosciences, Inc.

Pulse Biosciences Appoints Burke Barrett as President, CEO	May. 14	MT
Pulse Biosciences, Inc Announces CEO Changes	May. 14	CI
Pulse Biosciences, Inc Announces Executive Changes	May. 14	CI
Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System	May. 09	CI
Transcript : Pulse Biosciences, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
Pulse Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Sector Update: Health Care Stocks Slide Late Afternoon	Apr. 01	MT
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	Apr. 01	MT
Transcript : Pulse Biosciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024	Mar. 28
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28	CI
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 08	MT
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System	Mar. 08	MT
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System	Mar. 08	CI
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study	Feb. 14	CI
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	Jan. 02	MT
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp	Jan. 02	MT
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp	Jan. 02	CI
Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter	Dec. 20	CI
Pulse Biosciences Insider Bought Shares Worth $843,504, According to a Recent SEC Filing	Dec. 14	MT
Pulse Biosciences Insider Bought Shares Worth $1,117,085, According to a Recent SEC Filing	Dec. 01	MT
Pulse Biosciences Up 16% on Product Updates, Potential Stock Purchases by Duggan	Nov. 27	DJ
Pulse Biosciences Cleared to Start Catheter Ablation Feasibility Trial; Set to File Application for Cardiac Clamp; Shares Rise	Nov. 27	MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon	Nov. 21	MT
Sector Update: Health Care	Nov. 21	MT

Chart Pulse Biosciences, Inc.

Duration

Period

More charts

Company Profile

Pulse Biosciences, Inc. is a bioelectric medicine company. The Companyâs proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Companyâs Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-06-06 - Annual General Meeting

Related indices

Russell 2000

More about the company

	1st Jan change	Capi.
PULSE BIOSCIENCES, INC.	-29.08%	431M
THERMO FISHER SCIENTIFIC	+11.86%	227B
DANAHER CORPORATION	+15.51%	197B
INTUITIVE SURGICAL, INC.	+18.63%	141B
BOSTON SCIENTIFIC CORPORATION	+30.11%	110B
SIEMENS HEALTHINEERS AG	+0.65%	64.15B
EDWARDS LIFESCIENCES CORPORATION	+17.40%	53.72B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+5.82%	51.75B
AGILENT TECHNOLOGIES, INC.	+11.21%	45.2B
GE HEALTHCARE TECHNOLOGIES INC.	+5.74%	37.37B

Other Advanced Medical Equipment & Technology